Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s ...

(Reuters) -Cassava Sciences said on Monday it will stop all trials of its Alzheimer's disease drug after it failed a ...

Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences’ stock plummets 85% after its Alzheimer’s treatment trial fails. Investigations and regulatory scrutiny add ...

Pharma bro Martin Shkreli predicted Cassava Sciences stock would fall and the company would miss primary endpoints for its ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

Cassava Sciences (SAVA) announced that the topline results from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate AD did not meet ...

Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with ...